Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia

Leukemia and Lymphoma

Volumn 48, Issue 10, 2007, Pages 1940-1949

  Barr, Paul ^a   Fu, Pingfu ^b   Lazarus, Hillard ^a   Kane, Donna ^c   Meyerson, Howard ^a   Hartman, Paul ^a   Reyes, Rania ^a   Creger, Richard ^a   Stear, Karen ^a   Laughlin, Mary ^a   Tse, William ^a   Cooper, Brenda ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Clinical Trials Unit   (Ireland)

Author keywords

Chemotherapeutic approaches < neoplasia; Immunotherapy < neoplasia; Myeloid leukemias and dysplasias < neoplasia

Indexed keywords

CARBOPLATIN; FLUDARABINE; PYRIDOXINE; THALIDOMIDE; TOPOTECAN; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLEEDING; BLOOD LEVEL; BLOOD TOXICITY; BLOOD VESSEL PARAMETERS; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOLITIS; ESOPHAGITIS; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HEART TAMPONADE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; HYPOXIA; ILEUS; INFECTIOUS COMPLICATION; LABORATORY TEST; LIVER FAILURE; LIVER TOXICITY; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG TOXICITY; MALE; MUCOSAL BLEEDING; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; PANCYTOPENIA; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RASH; SIDE EFFECT; SKIN TOXICITY; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOGENICITY; THROMBOSIS; TUMOR REGRESSION; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; THALIDOMIDE; THROMBOCYTOPENIA; TOPOTECAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIDARABINE;

EID: 35148819763     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701573208     Document Type: Article

References (42)

1. Meyers, F. J., Welborn, J., Lewis, J. P. and Flynn, N. (1989) Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol, 7, pp. 173-178.
2. Martinez, J. A., Martin, G., Sanz, G. F., Sempere, A., Jarque, I. and de la Rubia, J. (1991) A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol, 9, pp. 39-43.
3. Vogler, W. R., Harrington, D. P., Winton, E. F., Lazarus, H. M., Bennett, J. M. and Cassileth, P. A. (1992) Phase II clinical trial of carboplatin in relapsed and refractory leukemia. Leukemia, 6, pp. 1072-1075.
4. Kantarjian, H. M., Beran, M., Ellis, A., Zwelling, L., O'Brien, S. and Cazenave, L. (1993) Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood, 81, pp. 1146-1151.
5. Rowinsky, E. K., Adjei, A., Donehower, R. C., Gore, S. D., Jones, R. J. and Burke, P. J. (1994) Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol, 12, pp. 2193-2203.
6. Furman, W. L., Baker, S. D., Pratt, C. B., Rivera, G. K., Evans, W. E. and Stewart, C. F. (1996) Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol, 14, pp. 1504-1511.
7. Kaufmann, S. H., Peereboom, D., Buckwalter, C. A., Svingen, P. A., Grochow, L. B. and Donehower, R. C. (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst, 88, pp. 734-741.
8. Cheng, M. F., Chatterjee, S. and Berger, N. A. (1994) Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res, 6, pp. 269-279.
9. Maliepaard, M., Nooter, K., Boersma, A. W., Verweij, J. and Stoter, G. (1998) Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol, 41, pp. 307-316.
10. Cooper, B. W., Veal, G. J., Radivoyevitch, T., Tilby, M. J., Meyerson, H. J. and Lazarus, H. M. (2004) A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Clin Cancer Res, 10, pp. 6830-6839.
11. Kaufmann, S. H., Karp, J. E., Letendre, L., Kottke, T. J., Safgren, S. and Greer, J. (2005) Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res, 11, pp. 6641-6649.
12. Fiedler, W., Graeven, U., Ergun, S., Verago, S., Kilic, N. and Stockschlader, M. (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 89, pp. 1870-1875.
13. Aguayo, A., Estey, E., Kantarjian, H., Mansouri, T., Gidel, C. and Keating, M. (1999) Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 94, pp. 3717-3721.
14. Padro, T., Ruiz, S., Bieker, R., Burger, H., Steins, M. and Kienast, J. (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, 95, pp. 2637-2644.
15. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P. and Eddlemon, P. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341, pp. 1565-1571.
16. Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L. and Nascimben, F. (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 98, pp. 958-965.
17. Weidner, N., Semple, J. P., Welch, W. R. and Folkman, J. (1991) Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med, 324, pp. 1-8.
18. Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L. and McCulloch, P. (1996) Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation. Eur J Cancer, 32, pp. 2474-2484.
19. Brown, L. D. (2001) Interval estimation for a binomial proportion. Stat Sci, 16, pp. 101-133.
20. Breems, D. A., Van Putten, W. L., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. and Verdonck, L. F. (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol, 23, pp. 1969-1978.
21. Leopold, L. H. and Willemze, R. (2002) The treatment of acute myeloid leukemia in first relapse: A comprehensive review of the literature. Leuk Lymphoma, 43, pp. 1715-1727.
22. Litzow, M. R. (2007) Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. Curr Opin Hematol, 14, pp. 130-137.
23. Visani, G., Tosi, P., Zinzani, P. L., Manfroi, S., Ottaviani, E. and Testoni, N. (1994) FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia, 8, pp. 1842-1846.
24. Steinmetz, H. T., Schulz, A., Staib, P., Scheid, C., Glasmacher, A. and Neufang, A. (1999) Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol, 78, pp. 418-425.
25. Giebel, S., Krawczyk-Kulis, M., Adamczyk-Cioch, M., Jakubas, B., Palynyczko, G. and Lewandowski, K. (2006) Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Ann Hematol, 85, pp. 717-722.
26. Clavio, M., Venturino, C., Pierri, I., Garrone, A., Miglino, M. and Canepa, L. (2004) Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol, 83, pp. 696-703.
27. Marcucci, G., Byrd, J. C., Dai, G., Klisovic, M. I., Kourlas, P. J. and Young, D. C. (2003) Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 101, pp. 425-432.
28. Karp, J. E., Gojo, I., Pili, R., Gocke, C. D., Greer, J. and Guo, C. (2004) Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-{beta}--arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res, 10, pp. 3577-3585.
29. Stone, R. M., DeAngelo, D. J., Klimek, V., Galinsky, I., Estey, E. and Nimer, S. D. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 105, pp. 54-60.
30. Harousseau, J-L, Lancet, J. E., Reiffers, J., Lowenberg, B., Thomas, X. and Huguet, F. (2007) A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood, 109, pp. 5151-5156.
31. Larson, R. A., Sievers, E. L., Stadtmauer, E. A., Lowenberg, B., Estey, E. H. and Dombret, H. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 104, pp. 1442-1452.
32. Steins, M. B., Padro, T., Bieker, R., Ruiz, S., Kropff, M. and Kienast, J. (2002) Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood, 99, pp. 834-839.
33. Thomas, D. A., Estey, E., Giles, F. J., Faderl, S., Cortes, J. and Keating, M. (2003) Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol, 123, pp. 436-441.
34. Cortes, J., Kantarjian, H., Albitar, M., Thomas, D., Faderl, S. and Koller, C. (2003) A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 97, pp. 1234-1241.
35. Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R. and Greipp, P. R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 24, pp. 431-436.
36. Dimopoulos, M. A. and Eleutherakis-Papaiakovou, V. (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med, 117, pp. 508-515.
37. Zangari, M., Barlogie, B., Thertulien, R., Jacobson, J., Eddleman, P. and Fink, L. (2003) Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymphoma, 4, pp. 32-35.
38. Zangari, M., Saghafifar, F., Anaissie, E., Badros, A., Desikan, R. and Fassas, A. (2002) Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis, 13, pp. 187-192.
39. Corso, A., Lorenzi, A., Terulla, V., Airo, F., Varettoni, M. and Mangiacavalli, S. (2004) Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol, 83, pp. 588-591.
40. Kaushal, V., Kaushal, G. P., Melkaveri, S. N. and Mehta, P. (2004) Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost, 2, pp. 327-334.
41. De Stefano, V., Sora, F., Rossi, E., Chiusolo, P., Laurenti, L. and Fianchi, L. (2005) The risk of thrombosis in patients with acute leukemia: Occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost, 3, pp. 1985-1992.
42. Vacca, A., Scavelli, C., Montefusco, V., Pietro, G Di, Neri, A. and Mattioli, M. (2005) Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol, 23, pp. 5334-5346.